OS Therapies Inc
OST-HER2
prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on OST-HER2 for prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma is in focus around Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“The Company anticipates a potential CMA decision by EMA in the fourth quarter of 2026.”